130 related articles for article (PubMed ID: 2133069)
1. Enhancement of tumour necrosis factor production and sensitivity to interleukin-2 of human peripheral blood mononuclear cells stimulated by lipopolysaccharide and muramyl dipeptide in vitro.
Rakhmilevich AL; Shneiderova MA; Korobko VG; Chuvpilo SA
Biomed Sci; 1990; 1(5):517-23. PubMed ID: 2133069
[TBL] [Abstract][Full Text] [Related]
2. [The stimulating action of lipopolysaccharide and muramyl dipeptide on the activation of mononuclear cells in human peripheral blood by recombinant interleukin-2 in vitro].
Rakhmilevich AL; Pelevina MA; Artsimovich NG; Fuks BB
Biull Eksp Biol Med; 1988 Dec; 106(12):698-701. PubMed ID: 3061497
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory properties of new conjugates of muramyl dipeptide and nor-muramyl dipeptide with retro-tuftsin (Arg-Pro-Lys-Thr-OMe).
Wardowska A; Dzierzbicka K; Trzonkowski P; Myśliwski A
Int Immunopharmacol; 2006 Oct; 6(10):1560-8. PubMed ID: 16919828
[TBL] [Abstract][Full Text] [Related]
4. Muramyl dipeptide and mononuclear cell supernatant induce Langhans-type cells from human monocytes.
Mizuno K; Okamoto H; Horio T
J Leukoc Biol; 2001 Sep; 70(3):386-94. PubMed ID: 11527988
[TBL] [Abstract][Full Text] [Related]
5. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
[TBL] [Abstract][Full Text] [Related]
6. [Activation of the production of the tumor-necrosis factor by the combined action of lipopolysaccharide and muramyl dipeptide in vitro and in vivo].
Fuks BB; Rakhmilevich AL; Pimenov AA; Dubrovskaia AG
Biull Eksp Biol Med; 1987 Oct; 104(10):497-9. PubMed ID: 3315036
[TBL] [Abstract][Full Text] [Related]
7. Modulation of lipopolysaccharide-induced cytokine gene expression in mouse bone marrow-derived macrophages by muramyl dipeptide.
Le Contel C; Temime N; Charron DJ; Parant MA
J Immunol; 1993 May; 150(10):4541-9. PubMed ID: 8482846
[TBL] [Abstract][Full Text] [Related]
8. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy.
Heaton KM; Ju G; Grimm EA
Cancer Res; 1993 Jun; 53(11):2597-602. PubMed ID: 8495422
[TBL] [Abstract][Full Text] [Related]
9. Secretion of interleukin-6 (IL-6) by human monocytes stimulated by muramyl dipeptide and tumour necrosis factor alpha.
Sancéau J; Falcoff R; Beranger F; Carter DB; Wietzerbin J
Immunology; 1990 Jan; 69(1):52-6. PubMed ID: 1690177
[TBL] [Abstract][Full Text] [Related]
10. Platelet-activating factor (PAF-acether) enhances the concomitant production of tumour necrosis factor-alpha and interleukin-1 by subsets of human monocytes.
Poubelle PE; Gingras D; Demers C; Dubois C; Harbour D; Grassi J; Rola-Pleszczynski M
Immunology; 1991 Feb; 72(2):181-7. PubMed ID: 2016118
[TBL] [Abstract][Full Text] [Related]
11. The incubation of human blood monocytes with tumor necrosis factor-alpha leads to lysis of tumor necrosis factor-sensitive but not resistant tumor cells.
Nii A; Fidler IJ
Lymphokine Res; 1990; 9(2):113-24. PubMed ID: 2338840
[TBL] [Abstract][Full Text] [Related]
12. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
13. Priming of human monocytes with PAF augments their production of tumor necrosis factor.
Rola-Pleszczynski M
J Lipid Mediat; 1990; 2 Suppl():S77-82. PubMed ID: 2133286
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
Meja KK; Barnes PJ; Giembycz MA
Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
[TBL] [Abstract][Full Text] [Related]
15. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.
Utsugi T; Sone S
J Immunol; 1986 Feb; 136(3):1117-22. PubMed ID: 3079797
[TBL] [Abstract][Full Text] [Related]
18. Influences of interleukins 2 and 4 on tumor necrosis factor production by murine mononuclear phagocytes.
McBride WH; Economou JS; Nayersina R; Comora S; Essner R
Cancer Res; 1990 May; 50(10):2949-52. PubMed ID: 2334896
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis.
Hart PH; Ahern MJ; Smith MD; Finlay-Jones JJ
Immunology; 1995 Apr; 84(4):536-42. PubMed ID: 7790026
[TBL] [Abstract][Full Text] [Related]
20. Modulation of tumour necrosis factor production with desmuramyldipeptide analogues.
Simcic S; Wraber B; Sollner M; Urleb U; Gobec S
Pflugers Arch; 2000; 440(5 Suppl):R64-6. PubMed ID: 11005615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
